Quarterly report pursuant to Section 13 or 15(d)

Out-license Agreements - Additional Information (Detail)

v3.22.1
Out-license Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended
Oct. 31, 2021
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2021
License Collaboration And Manufacturing Agreements [Line Items]              
License and collaboration revenue       $ 7,314,000   $ 3,552,000  
Deferred revenue - long-term       $ 45,000,000     $ 55,708,000
Bayer Research, Development, and License Agreement              
License Collaboration And Manufacturing Agreements [Line Items]              
Upfront cash payment received     $ 45,000,000.0        
Additional upfront reimbursement payment for research and process development     15,000,000.0        
Additional upfront cash payment entitle to receive for translational activities, invoiced amount     $ 1,300,000        
Royalty eligible to receive term after first commercial sale     12 years        
Determined upfront payment for license in order to evaluate transaction price     $ 45,000,000.0        
Determined research and process development activities in order to evaluate transaction price     15,000,000.0        
Determined additional specified translational activities in order to evaluate transaction price     5,000,000.0        
Bayer Research, Development, and License Agreement | Maximum              
License Collaboration And Manufacturing Agreements [Line Items]              
Additional upfront cash payment entitle to receive for translational activities     5,000,000.0        
Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones     $ 610,000,000.0        
Bayer Technology Transfer Agreement              
License Collaboration And Manufacturing Agreements [Line Items]              
License agreement amount invoiced percentage       40.00% 20.00%    
License agreement invoiced amount       $ 6,100,000 $ 3,100,000    
License agreement total fee           $ 15,300,000  
Technology transfer agreements fee remainder       The remainder of the fee will be billed as follows: (i) 20 percent on January 1, 2023 and (ii) 20 percent upon the technology transfer completion.      
Bayer Manufacturing Agreement              
License Collaboration And Manufacturing Agreements [Line Items]              
Written acceptance of binding purchase order percentage   50.00%       50.00%  
Bayer license agreement percentage of estimated supply price to be invoiced upon delivery   50.00%          
Total estimated supply price   $ 13,100,000          
Amount invoiced in March 2021 for 50% of total estimated supply price   $ 6,600,000          
Determined fee constituted entire consideration included in transaction price       $ 13,100,000      
License and collaboration revenue       6,600,000   $ 3,600,000  
Deferred revenue       50,900,000     $ 51,500,000
Development or sales-based milestone payments earned or received       0      
Pierre Fabre Commercialization Agreement              
License Collaboration And Manufacturing Agreements [Line Items]              
Upfront cash payment received $ 45,000,000.0            
Royalty eligible to receive term after first commercial sale 12 years            
Development or sales-based milestone payments earned or received       $ 0      
Years of manufacturing and supplying cost       7 years      
Determined upfront payment constituted entire consideration included in transaction price       $ 45,000,000      
Future royalty and sales-based milestone payments included in transaction price $ 0            
Pierre Fabre Commercialization Agreement | Long Term Liabilities              
License Collaboration And Manufacturing Agreements [Line Items]              
Deferred revenue - long-term       $ 45,000,000.0      
Pierre Fabre Commercialization Agreement | Maximum              
License Collaboration And Manufacturing Agreements [Line Items]              
Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones $ 318,000,000.0